Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Melanoma Brain Metastases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Alfred Health, Melbourne, Victoria, Australia
Contact: Study coordinator (Sally Haines, BNurs. GradCert (Pall.Care) · S.Haines@alfred.org.au · 03 9076
Contact: Principal Investigator (Dr Malaka Ameratunga)

Study leads

Malaka Ameratunga
Study Chair
Monash University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Melanoma · Brain Metastases

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Brain Cancer · Brain Metastases · Melanoma

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Boston, United States

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Cutaneous Melanoma · Brain Metastases

Abroad (travel likely)RecruitingPHASE1, PHASE2

Iowa City, United States · Salt Lake City, United States